General Information of Drug (ID: DMI3WFG)

Drug Name
AMG 334 Drug Info
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMI3WFG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ubrogepant DM749I3 Migraine 8A80 Approved [3]
Fremanezumab DMDZY54 Hyperprolactinaemia 5A60.1 Approved [4]
Galcanezumab DMIZ1E8 Hyperprolactinaemia 5A60.1 Approved [4]
Erenumab DMWMCN0 Hyperprolactinaemia 5A60.1 Approved [4]
Rimegepant DMHOAUG Migraine 8A80 Approved [5]
MK-3207 DM6OLGC Migraine 8A80 Phase 2 [6]
Telcagepant DMFT5D6 Cluster headache 8A81.0 Phase 2 [7]
Olcegepant DMVW5KR Migraine 8A80 Phase 2 [8]
BI-44370 DMZR9OU Migraine 8A80 Phase 2 [9]
LBR-101 DM4YA0D Migraine 8A80 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Calcitonin gene-related peptide receptor (CGRPR) TTY6O0Q CALRL_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02174861) A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.. U.S. National Institutes of Health.
2 EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
6 Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
7 CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5.
8 Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74.
9 BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84.
10 Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492.